Prosight Management, LP Cidara Therapeutics, Inc. Transaction History

Prosight Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$1.25 - $2.35 $448,703 - $843,563	-358,963 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$1.49 - $2.94 $206,661 - $407,775	138,699 Added 62.97%	358,963 $603,000
Q1 2019 May 15, 2019	SELL	$2.35 - $3.27 $59,925 - $83,385	-25,500 Reduced 10.38%	220,264 $584,000
Q4 2018 Feb 14, 2019	SELL	$2.1 - $4.5 $166,189 - $356,121	-79,138 Reduced 24.36%	245,764 $578,000
Q3 2018 Nov 15, 2018	SELL	$3.7 - $5.25 $3.09 Million - $4.38 Million	-833,798 Reduced 71.96%	324,902 $1.43 Million
Q2 2018 Aug 14, 2018	SELL	$3.75 - $6.05 $103,706 - $167,312	-27,655 Reduced 2.33%	1,158,700 $6.03 Million
Q1 2018 May 14, 2018	SELL	$4.0 - $8.15 $1.85 Million - $3.76 Million	-461,524 Reduced 28.01%	1,186,355 $4.75 Million
Q4 2017 Feb 13, 2018	BUY	$6.35 - $8.75 $10.5 Million - $14.4 Million	1,647,879	1,647,879 $11.2 Million

Ticker CDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,075,696
Market Cap $1.43B
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.